FedEx has launched a dedicated “FedEx Life Sciences” organization for healthcare and pharma logistics, disclosed on its Q4 FY2026 earnings call. The move formalizes a vertical that generated roughly $9 billion in healthcare transportation revenue in FY2025.
EVP and Chief Customer Officer Brie Carere said on the call that the company exited FY2026 with nearly $10 billion, though that figure has not yet been confirmed in a primary filing. Carere said the push is "backed by years of strategic investment in healthcare and life sciences.”
What it includes: FedEx Life Sciences brings together the company’s existing specialized life science centers across Europe and Asia Pacific under one organization. One asset bundled in is a temperature controlled air corridor between Dublin and Indianapolis. The route launched in 2025 and is being folded into the new organization rather than launched as a new service.
The targeted freight, including biologics, GLP-1 weight-loss drugs, and cell and gene therapies, requires strict cold chain, or temperature controlled, handling and commands premium rates. FedEx also recently spun off its LTL freight unit, concentrating resources on higher margin verticals including healthcare.
Across the sector: All three major parcel carriers are now building dedicated pharma logistics divisions at the same time:
The buildouts arrive ahead of healthcare contract cycles expected in 2027, when service tiers, certifications, and pricing are expected to become the key differentiators.
